EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia

Ibrahim Aldoss iD, Bijal D Shah iD, Jae H Park, Lori Muffly, Aaron C Logan iD, Patrick Brown, Wendy Stock, Elias J Jabbour iD

American Journal of Hematology · 2023-04 · 98 (4) · 666-680

DOI: 10.1002/ajh.26853 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 06.02.2023. Verfasst von Ibrahim Aldoss und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell, Antibodies, Bispecific. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 118 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent approvals of four CD19‐or CD22‐targeted therapies for B‐cell acute lymphoblastic leukemia (B‐ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B‐ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen‐targeted therapies for r/r B‐ALL and discuss considerations for their use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaLymphoma, B-CellAntibodies, BispecificAdultHumansImmunotherapy, AdoptiveAntigens, CD19Acute Disease

Substanzen

Antibodies, BispecificAntigens, CD19

Autor:innen und Institutionen

  • Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California, USA.
  • Division of Hematology/Oncology, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California, USA.
  • Bristol Myers Squibb, Princeton, New Jersey, USA.

ORCID-Profile: Ibrahim Aldoss, Bijal D Shah, Aaron C Logan, Elias J Jabbour

Zitieren

APA

Aldoss, I., Shah, B. D., Park, J. H., Muffly, L., Logan, A. C., Brown, P., Stock, W., & Jabbour, E. J. (2023). Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia. American Journal of Hematology, 98(4), 666-680. https://doi.org/10.1002/ajh.26853

Vancouver

Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, et al. Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia. American Journal of Hematology. 2023;98(4):666-680. doi:10.1002/ajh.26853

BibTeX
@article{Aldoss2023,
  author = {Aldoss, Ibrahim and Shah, Bijal D and Park, Jae H and Muffly, Lori and Logan, Aaron C and Brown, Patrick and Stock, Wendy and Jabbour, Elias J},
  title = {Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {4},
  pages = {666--680},
  doi = {10.1002/ajh.26853}
}
Kostenlos starten →